Objective: Painful chronic pancreatitis is often associated with main duct obstruction due to stones. Approaches to management are challenging, including surgery, extracorporeal shock wave lithotripsy, or endoscopic approaches. Here, we report our experience of pancreatoscopy + electrohydraulic lithotripsy (EHL) for pancreatic duct (PD) stones using SpyGlass.
P ain in chronic pancreatitis (CP) is often multifactorial. 1 A large multicenter study of 1000 patients with CP revealed obstruction of the main pancreatic duct (MPD) in 50%, due to strictures and stones in 32%, and stones alone in 18%. 2 Because painful CP may be associated with MPD obstruction due to stones, PD therapy is usually considered as a means to improve pain control. However, approaches to manage MPD stones, including extracorporeal shock wave lithotripsy (ESWL), Endoscopic Retrograde Cholangiopancreatography (ERCP) with stone clearance/ductal stenting, or surgery (eg, pancreaticojejunostomy) are challenging. Surgery has been shown to be more effective than endoscopic approaches. 3 However, pain relief with surgery is rarely achieved if pain control has not been gained with endoscopic duct decompression, and many patients prefer an attempt at nonsurgical approaches before embarking on surgery. Because traditional methods have their limitations, newer techniques, such as electrohydraulic lithotripsy (EHL) with directed visualization using pancreatoscopy, are considered. Cholangioscopy using the SpyGlass system (Legacy and DS; Boston Scientific, Boston, Mass) is increasingly used for treating difficult bile duct stones, with stone clearance in 90% to 100% and pain relief in more than 90%. 4, 5 In a recent overview by the European Society of Gastrointestinal Endoscopy in 2015, peroral cholangioscopy was included in the treatment options for bile duct stones, 6 but the European Society of Gastrointestinal Endoscopy guidelines from 2012 for PD stones did not specify a role for EHL in the treatment for pancreatic stones in CP. 1 In 2015, a new single-operator cholangiopancreatoscopy system was introduced, SpyGlass DS, which included improved operating characteristics, compared with the previous system (SpyGlass Legacy), with 4 times greater image resolution (240,000 pixels).
Here, we report our 3-year single-center experience of SpyGlass (Legacy and DS) pancreatoscopy and EHL for PD stones.
MATERIALS AND METHODS

Study Period
We retrospectively audited our unit's use of SpyGlass (Legacy and DS) EHL in the period from February 2013 to April 2016, with a focus on those patients undergoing pancreatic EHL.
Study Population
Patients fulfilled the M-ANNHEIM criteria for the diagnosis of CP. 7 All patients who were referred to our tertiary center for pain management related to CP from 2013 to 2016 were included in the study. All patients failed medical therapy and had previously undergone PD stenting without longstanding pain relief. They were all discussed in a multidisciplinary hepatopancreatobiliary meeting attended by specialist pancreaticobiliary surgeons, radiologists, and gastroenterologists, with an agreed decision to discuss with the patient the option of performing endoscopic treatment using EHL as the next step or the option of surgery.
Pancreatic Endoscopic Therapy
Dependent on the patient's previous tolerance of intravenous sedation for ERCP, either conscious sedation or deep propofol sedation was chosen to sedate the patients. All patients underwent ERCP combined with either SpyGlass Legacy or SpyGlass DS (the latter available since June 2015), allowing direct PD visualization and the application of EHL to stones by 1 trained operator (G.J.W.). Electrohydraulic lithotripsy was administered through a 1-mm probe passed down the working channel of the SpyGlass scope, with shocks applied at 80 to 100 J, 10 to 20 shocks per pulse, from a commercially available generator (Northgate Autolith Intracorporeal Electrohydraulic Lithotripsy iEHL Generator (9-201-00), Elgin, Ill).
Stone fragmentation was assessed directly using the SpyGlass and via fluoroscopy. Fragmented stones were trawled using 8.5-to 12-mm extraction balloons. Prophylactic pancreatic stents (5-7 Fr, 5-7 cm) were placed when indicated.
Outcome
Patients' baseline characteristics, procedural details, stone size and density (Hounsfield unit [HU] on CT imaging), clinical outcomes, and follow-up were assessed.
Main PD stone clearance was defined as successful stone fragmentation and removal with an extraction balloon. Duct decompression was defined as decrease in MPD size on followup imaging.
RESULTS
A total of 118 SpyGlass procedures combined with EHL were performed, 7% (n = 8) for MPD stones in 6 patients (3 female; mean [standard deviation or SD] age, 45 [7] years). All patients had radiological evidence of a dilated PD and main duct stone disease within 2 cm of the ampulla. Before EHL, all patients had undergone endoscopic attempts at stone clearance, including pancreatic sphincterotomy and at least 1 previous PD stenting trial. Six procedures (Table 1) were performed with SpyGlass Legacy and 2 procedures were performed with SpyGlass DS. The mean (SD) procedural time was 48 (15) minutes. For the pancreatograms and pancreatoscopic views, see Figure 1 , and Supplemental Digital Content 1, http://links.lww.com/MPA/A571 for a video of the pancreatoscopic procedure.
The mean (SD) size of dominant intraductal stones was 10.6 (3.9) mm, with stone density of 1235 (606) HU. Stone fragmentation, clearance, and duct decompression were achieved in 83% (5/6) of patients. Two patients required 2 EHL procedures to achieve clearance. In the patient with failed clearance, pancreatoscopy revealed that the stone (with low stone density at 197 HU) was not in the main duct but in the adjacent parenchyma/side branch, but with an associated stricture. There were no procedure-related complications.
All patients with successful EHL had pain relief/marked improvement at clinical review (mean [SD] follow-up, 2.7 [1.1] years). On imaging, magnetic resonance cholangiopancreatography and/or CT, all patients had decreased PD size. Two patients needed significantly less opiate analgesia compared with preprocedure, and the 3 others who were successfully treated did not require any analgesia.
DISCUSSION
In this study, we have demonstrated that in selected patients with an obstructing stone in the MPD, pancreatoscopy and visually directed EHL may facilitate successful stone clearance and duct decompression, leading to pain relief and avoidance of surgery.
European guidelines suggest ESWL as a first-line treatment when conventional ERCP fails to remove a MPD stone. 1 In biliary stones, ESWL, first reported in 1989, is successful in clearing 84% to 89% of stones, with cholangitis as the main adverse effect. 8, 9 Recently, a prospective study including 214 patients with CP showed similar MPD clearance rates, with a 4% complication rate reported. 10 This study also showed that more than 50% of patients needed at least 2 ESWL sessions and up to 11% needed more than 4 sessions before removal of stones with ERCP.
In the United Kingdom, access to ESWL is limited. Patients who undergo ESWL need admission after the procedure and an ERCP within 24 to 48 hours according to the local protocol, whereas pancreatosocopy combined with EHL is a day case requiring less than 4 hours in total. Another advantage of direct pancreatoscopy is that both ERCP and lithotripsy are performed in the same session, allowing both stone fragmentation and removal. ERCP also allows the treatment of PD strictures, as outlined in a recent report by Shin et al, 11 where a fully covered metal stent was inserted to dilate the stricture after stone removal with EHL.
Lastly, although this study and other studies did not show any SpyGlass/EHL-related complications, larger numbers are needed to further compare with ESWL data. 11, 12 Successful PD stone removal with EHL in this study was 83% and only failed in 1 patient whose stones were found to be in the side branch rather than the MPD. Because ESWL has poor success rates in patients with very dense, hard stones (attenuation value of >900 HU) and high body mass index values, 13 pancreatoscopy and visually directed EHL may have a particular role in MPD stones located in the head of pancreas that fail treatment after conventional ERCP. To further emphasize the latter, this current study has shown that despite a mean Hounsfield score of more than 1200 HU, EHL was still effective in fragmenting stones. Supporting this, Ito et al 14 showed that EHL was effective where ESWL had failed. Nevertheless, in a recent clinical practice study from Japan to treat MPD stones, ESWL was recommended as an option but not EHL. 15 The limitations of this current study are, of course, its retrospective nature and small procedure numbers to date. However, it provides an overview of early experiences with EHL for pancreatic stones using pancreatoscopy. More numbers and studies are needed to further assess the advantages of EHL over ESWL.
CONCLUSIONS
ERCP using SpyGlass pancreatoscopy + EHL has a role to play in the management of difficult obstructing pancreatic stones 
